GlassScriptPhysician profile
Meghan Lainoff
NPI 1902454366
$1,301.85
in general payments reported to CMS, 2019-2025
14 companies · $640 in 2025
The $640 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $662 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.59 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $201.34 | 2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $144.97 | 2024-2025 | |
| Janssen Biotech, INC. | $133.59 | 2024-2025 | Tremfya |
| Genzyme Corporation | $127.14 | 2024-2025 | |
| Ucb, INC. | $121.96 | 2024-2025 | Bimzelx |
| Abbvie INC. | $105.55 | 2024-2025 | |
| Organon LLC | $98.38 | 2025 | Vtama |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.00 | 2024 | Xifaxan |
| Incyte Corporation | $84.79 | 2024-2025 | Opzelura |
| Amgen INC. | $67.43 | 2024-2025 | Otezla, Otezla |
| Lilly USA, LLC | $50.16 | 2024 | Taltz |
| Helsinn Therapeutics (U.S.), INC. | $30.95 | 2024-2025 | Valchlor |
| Leo Pharma INC. | $22.90 | 2024 | Adbry |
| Kyowa Kirin, INC. | $22.69 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Lainoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.